Managing Biotechnology In A Network-Model Health Plan: A U.S. Private Payer Perspective
- 1 September 2006
- journal article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 25 (5) , 1347-1352
- https://doi.org/10.1377/hlthaff.25.5.1347
Abstract
Emerging biotechnology poses challenges to payers, including access, coverage, reimbursement, patient selection, and affordability. Premera Blue Cross, a private regional health plan, developed an integrated cross-functional approach to managing biologics, built around a robust formulary process that is fast, flexible, fair, and transparent to stakeholders. Results are monitored by cost and use reporting from merged pharmacy and medical claims. Utilization management and case management strategies will integrate with specialty pharmacy programs to improve outcomes and cost-effectiveness. Creative approaches to provider reimbursement can align providers’ incentives with those of the plan. Redesign of member benefits can also encourage appropriate use of biotechnology.Keywords
This publication has 4 references indexed in Scilit:
- ‘Follow-On Biologics’: Ensuring Continued Innovation In The Biotechnology IndustryHealth Affairs, 2006
- Do Oncologists Believe New Cancer Drugs Offer Good Value?The Oncologist, 2006
- National Health Spending In 2004: Recent Slowdown Led By Prescription Drug SpendingHealth Affairs, 2006
- Biotech drug market steadily expandsNature Biotechnology, 2005